US FDA inspection at Eugia Steriles ends with 5 observations, no impact stated

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹1499.50

prior close

₹1498.20

announcement price

After-mkt

timing

Nifty Midcap 150market+0.4%-0.7% vs market

Pharmaceuticals peers, median of 162sector+0.5%-0.7% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Midcap 150 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+0.3

15m

+0.3

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+0.4-0.7+0.5-0.7

Next day

+2.4-0.5+2.9+1.4+0.9

+2.1-0.4+2.6+1.0+1.1

+3.7-1.0+4.6+0.8+2.9

+2.6-1.3+3.9+0.9+1.7

+5.0-0.9+5.8+2.6+2.3

+4.2-0.2+4.4+2.3+2.0

15d

+3.5+0.4+3.2+4.3-0.7

+2.2-0.2+2.4+2.6-0.4

+7.3+2.0+5.4+2.8+4.5

+13.2-0.8+14.0+7.1+6.1

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA conducted a Pre-Approval Inspection (PAI) at Aurobindo Pharma's stepdown subsidiary Eugia Steriles in Andhra Pradesh from June 10 to June 19, 2026. The inspection concluded with 5 observations, which the company will respond to within the stipulated time. Aurobindo stated there is no impact on financials or operations from this inspection.

Likely market impact

5 observations is manageable and common, but any FDA follow-up such as a Form 483 or warning letter could affect future product approvals and US revenue.